CDRH’s Shuren Signals More Guidance, Enhanced Pre-Market Payer Role
This article was originally published in The Pink Sheet Daily
Executive Summary
CDRH Director Jeffrey Shuren details plans for new guidance documents and process changes at the device center, focused on IDE reviews, clinical testing requirements and pre-submission interactions with payers based on recommendations from the center’s entrepreneurs-in-residence program.
You may also be interested in...
Companion Diagnostics For Breakthrough Drugs Also Getting Swift Attention, FDA Says
Device center officials cite a host of formal and informal actions available under existing legislative authority to ensure that development and review of companion diagnostics do not hinder the ability of FDA-designated breakthrough therapies from coming to market.
The Pre-Decisional IDE: FDA’s New Proposal To Help Studies Get Started Right
FDA detailed its proposal for a new “pre-decisional IDE review process” in a revised draft guidance issued June 14. The voluntary process would occur prior to IDE submission and would offer companies comprehensive feedback on where their study plans fall short in gaining IDE approval and in ultimately gaining marketing approval.
New Metrics For Clinical Trial Oversight Floated By CDRH Entrepreneurs In Residence
Variability runs high in FDA’s process for approving new device trials, but the agency is open to recommendations for improvements coming out of its entrepreneurs-in-residence program, says Chip Hance, a former Abbott executive participating in the program.